The use of antioxidants in Friedreich's ataxia treatment

Expert Opinion on Investigational Drugs

Volumn 12, Issue 4, 2003, Pages 569-575

  Rustin, Pierre ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Cardiomyopathy; Idebenone; Mitochondria; Rare disease

Indexed keywords

ACONITATE HYDRATASE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; FRATAXIN; IDEBENONE; IRON; PLACEBO; SULFUR; UBIDECARENONE;

ANTIOXIDANT ACTIVITY; BRAIN FUNCTION; CARDIOMYOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG USE; FRIEDREICH ATAXIA; GENE FUNCTION; GENE LOSS; HEART MUSCLE CELL; HUMAN; HYPOTHESIS; IN VITRO STUDY; MITOCHONDRIAL RESPIRATION; NERVE CELL; OXIDATIVE STRESS; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; SYMPTOM; TREATMENT OUTCOME;

EID: 0037398112     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.4.569     Document Type: Review

References (34)

1. SCHULZ JB, DEHMER T, SCHOLS L et al.: Oxidative stress in patients with Friedreich ataxia. Neurology (2000) 55:1719-1721.
2. CHANTREL-GROUSSARD K, GEROMEL V et al.: Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum. Mol. Genet. (2001) 10:2061-2067.
3. PUCCIO H, KOENIG M: Friedreich ataxia: a paradigm for mitochondrial diseases. Curr. Opin. Genet. Dev. (2002) 12:272-277.
4. RUSTIN P, MUNNICH A, ROTIG A: Quinone analogs prevent enzymes targeted in Friedreich ataxia from iron-induced injury in vitro. Biofactors (1999) 9:247-251.
5. DURR A, COSSEE M, AGID Y et al.: Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. (1996) 335:1169-1175.
6. HARDING AE: Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain (1981) 104:589-620.
7. HANAUER A, CHERY M, FUJITA R, DRIESEL AJ, GILGENKRANTZ S, MANDEL JL. The Friedreich ataxia gene is assigned to chromosome 9q13-q21 by mapping of tightly linked markets and shows linkage disequilibrium, with D9S15. Am. J. Hum. Genet. (1990) 46:133-137.
8. CAMPUZANO V, MONTERMINI L, MOLTO MD et al.: Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (1996) 271:1423-1427.
9. VETCHER AA, NAPIERALA M, IYER RR, CHASTAIN PD, GRIFFITH JD, WELLS RD: Sticky DNA, a long GAA.GAA. TTC triplex that is formed intramolecularly, in the sequence of intron 1 of the frataxin gene. J. Biol. Chem. (2002) 277:39217-39227.
10. SAKAMOTO N, OHSHIMA K, MONTERMINI L, PANDOLFO M, WELLS RD: Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J. Biol. Chem. (2001) 276:27171-27177.
11. CAMPUZANO V, MONTERMINI L, LUTZ Y et al.: Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. (1997) 6:1771-1780.
12. MUHLENHOFF U, RICHHARDT N, RISTOW M, KISPAL G, LILL R: The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/ S proteins. Hum. Mol. Genet. (2002) 11:2025-2036.
13. DUBY G, FOURY F, RAMAZZOTTI A, HERRMANN J, LUTZ T: A non-essential function for yeast frataxin in iron-sulfur cluster assembly. Hum. Mol. Genet. (2002) 11:2635-2643.
14. ROTIG A, DE LONLAY P, CHRETIEN D et al.: Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. (1997) 17:215-217.
15. PARASKEVA E, HENTZE MW: Iron-sulphur clusters as genetic regulatory switches: the bifunctional iron regulatory protein-1. FEBS Lett. (1996) 389:40-43.
16. HENTZE MW, KUHN LC: Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. USA (1996) 93:8175-8182.
17. PANTOPOULOS K, HENTZE MW: Activation of iron regulatory protein-1 by oxidative stress in vitro. Proc. Natl. Acad. Sci. USA (1998) 95:10559-10563.
18. HENTZE MW: Translational control by iron-responsive elements. Adv. Exp. Med. Biol. (1994) 356:119-126.
19. RUSTIN P: Frataxin and mitochondrial iron. In: Molecular and Cellular Iron Transport. DM Templeton (Ed.) Marcel Dekker, Inc., New York/Basel (2002):255-272.
20. BABCOCK M, DE SILVA D, OAKS R et al.: Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science (1997) 276:1709-1712.
21. FOURY F: Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett. (1999) 456:281-284.
22. RUSTIN P, VON KLEIST-RETZOW JC, CHANTREL-GROUSSARD K, SIDI D, MUNNICH A, ROTIG A: Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet (1999) 354:477-479.
23. ROTIG A, SIDI D, MUNNICH A, RUSTIN P: Molecular insights into Friedreich's ataxia and antioxidant-based therapies. Trends Mol. Med. (2002) 8:221-224.
24. PORTER KHJ: Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br. J. Hematol. (1993) 85:393-400.
25. HAUSSE AO, AGGOUN Y, BONNET D et al.: Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart (2002) 87:346-349.
26. NIENHUIS A: Vitamin C and iron. N. Engl. J. Med. (1981) 304:170-171.
27. ERNSTER L, DALLNER G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta (1995) 1271:195-204.
28. GEROMEL V, DARIN N, CHRETIEN D et al.: Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol. Genet. Metab. (2002) 77:21.
29. ROTIG A, APPELKVIST EL, GEROMEL V et al.: Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet (2000) 356:391-395.
30. BUNSE M, BIT-AVRAGIM N, RIEFFLIN A et al.: Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia. Ann. Neurol. (2003) 53:121-123.
31. SCHOLS L, VORGERD M, SCHILLINGS M, SKIPKA G, ZANGE J: Idebenone in patients with Friedreich ataxia. Neurosci. Lett. (2001) 306:169-172.
32. SORENSEN L, EKSTRAND M, SILVA JP et al.: late-onset corticohippocampal neurodepletion attributable to catastrophic failure of oxidative phosphorylation in MILON mice. J. Neurosci. (2001) 21:8082-8090.
33. ARTUCH R, ARACIL A, MAS A et al.: Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics (2002) 33:190-193.
34. LODI R, HART PE, RAJAGOPALAN B et al.: Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol. (2001) 49:590-596.